Sugi Predict

Sugi Predict / Compounds / SCHEMBL1471097

SCHEMBL1471097

SCHEMBL1471097

CCCCCC(O)c1ccc(CN(CCCCCCC(=O)O)S(C)(=O)=O)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ PTGER2 P43116 4/20 0.49
▸ LTB4R Q15722 1/20 0.47
▸ CACNA1F O60840 1/20 0.47
▸ CHRM2 P08172 1/20 0.47
▸ ADRA2B P18089 1/20 0.47
▸ ADRA2C P18825 1/20 0.47
▸ CHRM3 P20309 1/20 0.47
▸ HTR2A P28223 1/20 0.47
▸ SLC6A4 P31645 1/20 0.47
▸ DRD3 P35462 1/20 0.47
▸ CACNA1D Q01668 1/20 0.47
▸ KCNH2 Q12809 1/20 0.47
▸ CACNA1S Q13698 1/20 0.47
▸ CACNA1C Q13936 1/20 0.47
▸ PTGER4 P35408 1/20 0.46
▸ PTGER3 P43115 1/20 0.46
▸ FFAR4 Q5NUL3 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5725268 0.98 PTGER2 (0.46) PTGER2LTB4RCACNA1FCHRM2ADRA2B
SCHEMBL4628656 0.90 PTGER2 (0.42) PTGER2LTB4R
SCHEMBL5725576 0.89 CNR2 (0.51) PTGER2LTB4RCACNA1FCHRM2ADRA2B
SCHEMBL1471278 0.87 CNR2 (0.53) PTGER2
SCHEMBL1471108 0.87 ALDH1A1 (0.47) PTGER2CACNA1FCHRM2ADRA2BADRA2C
SCHEMBL5725323 0.87 MAPT (0.44) LTB4R
SCHEMBL5726939 0.85 LMNA (0.45) —
SCHEMBL14569238 0.84 S1PR1 (0.52) —
SCHEMBL1471694 0.84 PTGER2 (0.41) PTGER2LTB4RPTGER4PTGER3
SCHEMBL5725704 0.84 LTB4R2 (0.42) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1917238-A2 SULFONAMIDES Allergan, Inc. (US) 2008-05-07 — — EP claimed
EP-0951282-B1 PREVENTION AND TREATMENT OF SKELETAL DISORDER WITH EP2 RECEPTOR SUBTYPE SELECTIVE PROSTAGLANDIN E2 AGONISTS PFIZER (US) 2008-04-02 — — EP claimed
US-20070142471-A1 SULFONAMIDES ALLERGAN, INC. 2007-06-21 — — US claimed
WO-2007024860-A2 SULFONAMIDES ALLERGAN, INC. (US) 2007-03-01 — — WO claimed
EP-0946501-B1 PREVENTION OF LOSS AND RESTORATION OF BONE MASS BY CERTAIN PROSTAGLANDIN AGONISTS PFIZER (US) 2006-05-31 — — EP claimed
US-6998423-B2 Prevention of loss and restoration of bone mass by certain prostaglandin agonists PFIZER INC. (US) 2006-02-14 — — US claimed
US-20040176461-A1 Prevention of loss and restoration of bone mass by certain prostaglandin agonists PFIZER INC 2004-09-09 — — US claimed
EP-1448182-A1 PHARMACEUTICAL COMPOSITIONS AND METHODS FOR ADMINISTERING EP 2 RECEPTOR SELECTIVE AGONISTS Pfizer Products Inc. (US) 2004-08-25 — — EP claimed
US-20030166631-A1 Pharmaceutical compositions and methods for administering EP2 receptor selective agonists DUMONT FRANCIS (US) 2003-09-04 — — US claimed
WO-2003045371-A1 PHARMACEUTICAL COMPOSITIONS AND METHODS FOR ADMINISTERING EP2 RECEPTOR SELECTIVE AGONISTS PFIZER PRODUCTS INC. (US) 2003-06-05 — — WO claimed
US-20030105092-A1 Prevention of loss and restoration of bone mass by certain prostaglandin agonists CAMERON KIMBERLEY Q (US) 2003-06-05 — — US claimed
US-20020016368-A1 Prevention of loss and restoration of bone mass by certain prostaglandin agonists CAMERON KIMBERLY O (US) 2002-02-07 — — US claimed
US-6288120-B1 Prevention of loss and restoration of bone mass by certain prostaglandin agonists PFIZER INC. 2001-09-11 — — US claimed
EP-1108426-A2 Use of prostaglandin agonists to treat erectile dysfunction or impotence Pfizer Products Inc. (US) 2001-06-20 — — EP claimed
JP-2000507961-A — — 2000-06-27 — — JP claimed
CN-1241176-A Prevention of loss and restoration of bone mass by certain prostaglandin agonists PFIZER (US) 2000-01-12 — — CN claimed
EP-0951282-A1 PREVENTION AND TREATMENT OF SKELETAL DISORDER WITH EP2 RECEPTOR SUBTYPE SELECTIVE PROSTAGLANDIN E2 AGONISTS PFIZER INC. (US) 1999-10-27 — — EP claimed
EP-0946501-A1 PREVENTION OF LOSS AND RESTORATION OF BONE MASS BY CERTAIN PROSTAGLANDIN AGONISTS PFIZER INC. (US) 1999-10-06 — — EP claimed
WO-1998027976-A1 PREVENTION AND TREATMENT OF SKELETAL DISORDER WITH EP2 RECEPTOR SUBTYPE SELECTIVE PROSTAGLANDIN E2 AGONISTS PFIZER INC. (US) 1998-07-02 — — WO claimed
WO-1998028264-A1 PREVENTION OF LOSS AND RESTORATION OF BONE MASS BY CERTAIN PROSTAGLANDIN AGONISTS PFIZER INC. (US) 1998-07-02 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040176461-A1 Prevention of loss and restoration of bone mass by certain prostaglandin agonists HPGDS, PTGIR, PTGER1 PTGER2 12/4885LTB4R 44/4885CACNA1F 2667/4885
US-20020016368-A1 Prevention of loss and restoration of bone mass by certain prostaglandin agonists HPGDS, PTGIR, PTGER1 PTGER2 12/4885LTB4R 44/4885CACNA1F 2667/4885
US-20030105092-A1 Prevention of loss and restoration of bone mass by certain prostaglandin agonists HPGDS, PTGIR, PTGER1 PTGER2 12/4885LTB4R 44/4885CACNA1F 2667/4885
US-20070142471-A1 SULFONAMIDES CRYZ, QDPR, GLRX3 PTGER2 1557/4885LTB4R 1952/4885CACNA1F 961/4885
US-20030166631-A1 Pharmaceutical compositions and methods for administering EP2 receptor selective agonists PTGER2, PTGER1, PTGFR PTGER2 1/4885LTB4R 101/4885CACNA1F 3211/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.